Company profile

Grifols SA

NASDAQ:GRFSBiotechnology: Pharmaceutical Preparations

Drug pipeline (5)

AssetStageRevenueTrialsStatus
.ALPHA.1-PROTEINASE INHIBITOR HUMANapproved6approved
ANTITHROMBIN III HUMANapproved1approved
FACTOR IX COMPLEXapproved0
PLASMA PROTEIN FRACTION (HUMAN)approved0
Sodium Chlorideapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (75)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT07582432phase3recruiting2026-04-232028-08-31Grifols Biologicals, LLCA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
NCT00418483phase1completed2007-03-012010-04-01Grifols Therapeutics LLCA Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion
NCT07555483phase3recruiting2026-05-052027-09-30Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT01014975phase1_2completed2009-11-012013-11-01Grifols Therapeutics LLCA Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
NCT01222117phase2completed2010-12-012015-12-01Grifols Therapeutics LLCA Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

FDA applications (22)

ApplicationTypeApplicantProducts
ANDA 207956ANDALABORATORIOS GRIFOLS SA
BLA 101130BLAGrifols Therapeutics LLC
BLA 101134BLAGrifols Therapeutics LLC
BLA 101138BLAGrifols Therapeutics LLC
BLA 101140BLAGrifols Therapeutics LLC